Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.56 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.55 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.46 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.45 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8900388 | 0.98 | PTGS2 (0.54) | PTGS2GLASTING1AKR1B1TDP1 | |
| SCHEMBL29363967 | 0.98 | PTGS2 (0.57) | PTGS2GLASTING1AKR1B1TDP1 | |
| SCHEMBL228994 | 0.98 | PTGS2 (0.57) | PTGS2GLASTING1AKR1B1TDP1 | |
| Acetic Acid SCHEMBL27649054 | 0.94 | PTGS2 (0.54) | PTGS2GLASTING1AKR1B1TDP1 | |
| Formic Acid SCHEMBL28053598 | 0.89 | PTGS2 (0.50) | PTGS2GLASTING1AKR1B1TDP1 | |
| Hydrochloric Acid SCHEMBL2527505 | 0.83 | CTBP2 (0.59) | PTGS2AKR1B1TDP1KDM4EMAPT | |
| SCHEMBL19475173 | 0.83 | PTGS2 (0.55) | PTGS2GLASTING1AKR1B1TDP1 | |
| Hydrochloric Acid SCHEMBL14167164 | 0.82 | P2RX7 (0.43) | PTGS2GLASTING1TDP1MAPT | |
| SCHEMBL7188564 | 0.82 | L3MBTL1 (0.43) | PTGS2GLASTING1SMN1; SMN2KDM4E | |
| SCHEMBL1258807 | 0.82 | ESR1 (0.43) | PTGS2GLASTING1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4091655-B2 | — | — | 2008-05-28 | — | — | JP | claimed |
| EP-0831820-A1 | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALKANOL COMPOUNDS IN SOLUTION FORM | HOECHST MARION ROUSSEL, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0766668-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF | HOECHST MARION ROUSSEL, INC. (US) | 1997-04-09 | — | — | EP | claimed |
| WO-1996039139-A1 | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALKANOL COMPOUNDS IN SOLUTION FORM | HOECHST MARION ROUSSEL, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1995031437-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF | HOECHST MARRION ROUSSEL, INC. (US) | 1995-11-23 | — | — | WO | claimed |
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | disclosed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013029648-A1 | NEW AMINOACID COMPOUNDS FOR TREATING TUMOURS AND AUTOIMMUNE DISEASES | ARKE' ORGANICS S.R.L. (IT) | 2013-03-07 | — | — | WO | disclosed |
| US-8129408-B2 | Pharmaceutical composition for piperidinoalkanol compounds | AVENTISUB II INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100021547-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1399422-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL] -1-HYDROXYBUTYL] -A,A-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002102777-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-12-27 | — | — | WO | disclosed |
| EP-0998272-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALKANOL-DECONGESTANT | HOECHST MARION ROUSSEL, INC. (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999009957-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALKANOL-DECONGESTANT | HOECHST MARION ROUSSEL, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0831820-A1 | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALKANOL COMPOUNDS IN SOLUTION FORM | HOECHST MARION ROUSSEL, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0812195-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | HOECHST MARION ROUSSEL, INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0766668-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF | HOECHST MARION ROUSSEL, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996039139-A1 | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALKANOL COMPOUNDS IN SOLUTION FORM | HOECHST MARION ROUSSEL, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996026726-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | HOECHST MARION ROUSSEL, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1995031437-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF | HOECHST MARRION ROUSSEL, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021547-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | PKD1, CFTR, PKD2 | PTGS2 2183/4885GLA 3705/4885GAA 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.